NASDAQ:ENTA - Enanta Pharmaceuticals Stock Price, News, & Analysis

Enanta Pharmaceuticals trades on the NASDAQ under the ticker symbol "ENTA."

Enanta Pharmaceuticals Inc (NASDAQ:ENTA) announced its quarterly earnings results on Wednesday, February, 6th. The biotechnology company reported $1.25 earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of $1.46 by $0.21. The biotechnology company had revenue of $69.89 million for the quarter, compared to the consensus estimate of $71.27 million. Enanta Pharmaceuticals had a net margin of 36.19% and a return on equity of 22.78%. Enanta Pharmaceuticals's revenue was up 83.4% on a year-over-year basis. During the same period last year, the business earned $0.59 EPS. View Enanta Pharmaceuticals' Earnings History.

Enanta Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, May 14th 2019. View Earnings Estimates for Enanta Pharmaceuticals.

5 brokerages have issued 1-year target prices for Enanta Pharmaceuticals' stock. Their forecasts range from $80.00 to $133.00. On average, they expect Enanta Pharmaceuticals' share price to reach $108.25 in the next twelve months. This suggests a possible upside of 29.5% from the stock's current price. View Analyst Price Targets for Enanta Pharmaceuticals.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Enanta Pharmaceuticals in the last year. There are currently 3 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Enanta Pharmaceuticals.

News articles about ENTA stock have been trending negative on Monday, according to InfoTrie Sentiment. The research firm scores the sentiment of media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Enanta Pharmaceuticals earned a daily sentiment score of -2.3 on InfoTrie's scale. They also assigned news coverage about the biotechnology company a news buzz of 2.0 out of 10, indicating that recent media coverage is very unlikely to have an effect on the stock's share price in the near term.

Some companies that are related to Enanta Pharmaceuticals include Perrigo (PRGO), Catalent (CTLT), Amarin (AMRN), GALAPAGOS NV/S (GLPG), Nektar Therapeutics (NKTR), Alkermes (ALKS), Array Biopharma (ARRY), GW Pharmaceuticals PLC- (GWPH), Horizon Pharma (HZNP), Ascendis Pharma A/S (ASND), United Therapeutics (UTHR), TESARO (TSRO), Taro Pharmaceutical Industries (TARO), FibroGen (FGEN) and HUTCHISON CHINA/S (HCM).

Based on aggregate information from My MarketBeat watchlists, some companies that other Enanta Pharmaceuticals investors own include Cronos Group (CRON), Dollar Tree (DLTR), Intercept Pharmaceuticals (ICPT), Gilead Sciences (GILD), NVIDIA (NVDA), Zoetis (ZTS), GW Pharmaceuticals PLC- (GWPH), Micron Technology (MU), Celgene (CELG) and Exelixis (EXEL).

Enanta Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include First Manhattan Co. (3.42%), Eqis Capital Management Inc. (0.03%), Virtu Financial LLC (0.01%), Meeder Asset Management Inc. (0.01%), Valeo Financial Advisors LLC (0.00%) and Financial Gravity Wealth Inc. (0.00%). Company insiders that own Enanta Pharmaceuticals stock include Bruce L A Carter, George Golumbeski, Jay R Luly, Nathalie Adda, Nathaniel S Gardiner, Paul J Mellett, Tim Ocain and Yat Sun Or. View Institutional Ownership Trends for Enanta Pharmaceuticals.

ENTA stock was sold by a variety of institutional investors in the last quarter, including First Manhattan Co. and Meeder Asset Management Inc.. Company insiders that have sold Enanta Pharmaceuticals company stock in the last year include Bruce L A Carter, George Golumbeski, Jay R Luly, Nathalie Adda, Nathaniel S Gardiner, Paul J Mellett, Tim Ocain and Yat Sun Or. View Insider Buying and Selling for Enanta Pharmaceuticals.

ENTA stock was purchased by a variety of institutional investors in the last quarter, including Virtu Financial LLC, Eqis Capital Management Inc., Valeo Financial Advisors LLC and Financial Gravity Wealth Inc.. View Insider Buying and Selling for Enanta Pharmaceuticals.

Shares of ENTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of ENTA stock can currently be purchased for approximately $83.59.

Enanta Pharmaceuticals has a market capitalization of $1.63 billion and generates $206.63 million in revenue each year. The biotechnology company earns $71.95 million in net income (profit) each year or $3.48 on an earnings per share basis. Enanta Pharmaceuticals employs 113 workers across the globe.

The official website for Enanta Pharmaceuticals is http://www.enanta.com.

Enanta Pharmaceuticals' mailing address is 500 ARSENAL STREET, WATERTOWN MA, 02472. The biotechnology company can be reached via phone at 617-607-0800 or via email at [email protected]